A synthetic virus-like assembly unlocks dual-antigen presentation for broad-spectrum anti-SARS-CoV-2 immunity
- 1Shandong WeigaoLitong Biological Products Co., Ltd.
- 2Weirui Biotechnology (Kunming) Co., Ltd., Ciba Biotechnology Innovation Center
Abstract
In the present study, by building on the previous development of a DC-SIGN-targeting virus-like structure (VLS) vaccine platform and a comprehensive characterization of SARS-CoV-2 structural biology, particularly insights into the role of the nucleocapsid (N) protein in eliciting cytotoxic T lymphocyte (CTL) responses during infection, we designed a SARS-CoV-2 virion-mimetic structural vaccine that encapsulates an mRNA encoding the spike S1 antigen complexed with N protein complexes, with S1 proteins loaded on its surface. This characterized virion-mimetic structural vaccine not only induces the production of high-efficiency antibodies against both the spike and N proteins but also elicits robust S1-specific and N-specific CTL responses in animal models. Furthermore, the generated antibodies exhibit cross-reactive neutralizing activity against multiple SARS-CoV-2 variants and provide protective immunity against challenge with mutant viruses in immunized hosts. This SARS-CoV-2 virion-mimetic structure effectively recapitulates natural infection pathways, comprehensively activating the innate immune system and thereby creating an optimal microenvironment for eliciting potent and broad-spectrum adaptive immune responses.
Related
- Major Histocompatibility Complex (MHC) and Fungal Antigen Presentation: Immunological Mechanisms and Their Role in Anti-Fungal Immunity
- Clinical observations of features in spectrum domain optical coherence tomography of amiodarone-induced retinopathy: Two case presentation
- Commentary: A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosis across the spectrum of disease
- Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer
- ChronIQ-DRx2: restoring unwritten clinical decision logic unlocks personalized chronic disease management
BibTeX
@article{zhang2026synthetic,
title = {{A synthetic virus-like assembly unlocks dual-antigen presentation for broad-spectrum anti-SARS-CoV-2 immunity}},
author = {Jingjing Zhang and Fengyuan Zeng and Yanmei Li and Yixuan Wang and Zhenxiao Zhang and Changyong Mu and Change Liu and Yanrui Su and Xiaowu Peng and Lin Feng and Dongxiu Gao and Lichun Wang and An Wang and Miaomiao Xing and Lihong Sun and Zixiong Guo and Huijuan Li and Hui Zhang and Xiaoxia Yu and Bing Xie and Lu Liu and Liping He and Zhixiao Zhang and Dongbao Wang and Fang Zhang and Lichun Zheng and Fuyun He and Hongkun Yi and Kaili Ma and Qihan Li},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-63144-4},
url = {https://doi.org/10.1038/s41598-026-63144-4},
note = {CC BY},
}
RIS
TY - JOUR
TI - A synthetic virus-like assembly unlocks dual-antigen presentation for broad-spectrum anti-SARS-CoV-2 immunity
AU - Jingjing Zhang
AU - Fengyuan Zeng
AU - Yanmei Li
AU - Yixuan Wang
AU - Zhenxiao Zhang
AU - Changyong Mu
AU - Change Liu
AU - Yanrui Su
AU - Xiaowu Peng
AU - Lin Feng
AU - Dongxiu Gao
AU - Lichun Wang
AU - An Wang
AU - Miaomiao Xing
AU - Lihong Sun
AU - Zixiong Guo
AU - Huijuan Li
AU - Hui Zhang
AU - Xiaoxia Yu
AU - Bing Xie
AU - Lu Liu
AU - Liping He
AU - Zhixiao Zhang
AU - Dongbao Wang
AU - Fang Zhang
AU - Lichun Zheng
AU - Fuyun He
AU - Hongkun Yi
AU - Kaili Ma
AU - Qihan Li
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-63144-4
UR - https://doi.org/10.1038/s41598-026-63144-4
AB - In the present study, by building on the previous development of a DC-SIGN-targeting virus-like structure (VLS) vaccine platform and a comprehensive characterization of SARS-CoV-2 structural biology, particularly insights into the role of the nucleocapsid (N) protein in eliciting cytotoxic T lymphocyte (CTL) responses during infection, we designed a SARS-CoV-2 virion-mimetic structural vaccine that encapsulates an mRNA encoding the spike S1 antigen complexed with N protein complexes, with S1 proteins loaded on its surface. This characterized virion-mimetic structural vaccine not only induces the production of high-efficiency antibodies against both the spike and N proteins but also elicits robust S1-specific and N-specific CTL responses in animal models. Furthermore, the generated antibodies exhibit cross-reactive neutralizing activity against multiple SARS-CoV-2 variants and provide protective immunity against challenge with mutant viruses in immunized hosts. This SARS-CoV-2 virion-mimetic structure effectively recapitulates natural infection pathways, comprehensively activating the innate immune system and thereby creating an optimal microenvironment for eliciting potent and broad-spectrum adaptive immune responses.
SN - 2045-2322
ER -